Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jan 17, 2023 - P1b/2 | N=7 | Terminated | Sponsor: M.D. Anderson Cancer Center | Completed ➔ Terminated; The sponsor sold the drug TALADEGIB to another company during the trial and thereafter no drug was available. The sponsor made a decision to stop development of this drug Taladegib.
Combination therapy • Trial termination • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor
|